In January 2012 Celgene (NASDAQ: CELG) acquired Avila Therapeutics to pursue development of the company’s Btk inhibitor and covalent drug discovery platform.
| Headquarters | Bedford, MA |
| Pipeline | Phase 2 Btk program advancing at Celgene |
Avila Therapeutics
